Hypertensive heart disease. A complex syndrome or a hypertensive
... increase in fibroblastic activity that occurs in hypertensive heart disease may be an important factor in pathological rather than physiological left ventricular hypertrophy. Cardiac myocytes of the left ventricle are enlarged in hypertensive heart disease[46] and fibrosis is another feature of the ...
... increase in fibroblastic activity that occurs in hypertensive heart disease may be an important factor in pathological rather than physiological left ventricular hypertrophy. Cardiac myocytes of the left ventricle are enlarged in hypertensive heart disease[46] and fibrosis is another feature of the ...
Pulmonary Vascular Diseases
... shown to increase RV inotropy4 and decrease RV hypertrophy,5 in addition to its effects on the pulmonary circulation), others might have untoward effects on the RV. For example, imatinib, an antiproliferative/proapoptotic agent that shows preliminary promise in reversing pulmonary vascular remodelin ...
... shown to increase RV inotropy4 and decrease RV hypertrophy,5 in addition to its effects on the pulmonary circulation), others might have untoward effects on the RV. For example, imatinib, an antiproliferative/proapoptotic agent that shows preliminary promise in reversing pulmonary vascular remodelin ...
Embolic Strokes of Undetermined Source in the Athens Stroke
... for the opposite; still, this may be explained by the fact that strokes caused by paroxysmal AF (like ESUS) are less severe compared with strokes caused by persistent or permanent AF.13 In this context, patients with ESUS seem to be appropriate candidates for prolonged ECG recording either in a noni ...
... for the opposite; still, this may be explained by the fact that strokes caused by paroxysmal AF (like ESUS) are less severe compared with strokes caused by persistent or permanent AF.13 In this context, patients with ESUS seem to be appropriate candidates for prolonged ECG recording either in a noni ...
Left Ventricular Diastolic Mechanical Dyssynchrony and Associated
... were placed during the same cardiac cycles at the mitral annulus, basal interventricular septum, midlateral LV wall, and midseptum. For clarity, in A, only the mitral annulus (yellow) and basal septum (cyan) curves are demonstrated. In B, curves from all 4 points are demonstrated in the same cardiac ...
... were placed during the same cardiac cycles at the mitral annulus, basal interventricular septum, midlateral LV wall, and midseptum. For clarity, in A, only the mitral annulus (yellow) and basal septum (cyan) curves are demonstrated. In B, curves from all 4 points are demonstrated in the same cardiac ...
PULMONARY HYPERTENSION AND ANESTHESIA R N. K
... mismatch (figure 5). Inhalation anesthetics inhibit hypoxic pulmonary vasoconstriction, thus blood is not shifted away from the nonfunctional alveolus, and V/Q mismatch is high. The use of nitric oxide will shift blood from the nonfunctional alveolus to the functional one, reducing shunting of blood ...
... mismatch (figure 5). Inhalation anesthetics inhibit hypoxic pulmonary vasoconstriction, thus blood is not shifted away from the nonfunctional alveolus, and V/Q mismatch is high. The use of nitric oxide will shift blood from the nonfunctional alveolus to the functional one, reducing shunting of blood ...
Aortic Valve Replacement
... Rahimtoola suggested that the degree of PPM could be quantified, which would aid in identifying patients at risk of clinical sequelae caused by this condition. The pathophysiology of mismatch was subsequently proposed to be related to persistent valve gradients based on in vitro studies conducted by ...
... Rahimtoola suggested that the degree of PPM could be quantified, which would aid in identifying patients at risk of clinical sequelae caused by this condition. The pathophysiology of mismatch was subsequently proposed to be related to persistent valve gradients based on in vitro studies conducted by ...
an ultrasound technique Mitral valve movement - Heart
... diagnostic value in mitral valve disease. In addition, because of the new type of information that is given, it has potential as a research tool which is, as yet, largely unexplored. ...
... diagnostic value in mitral valve disease. In addition, because of the new type of information that is given, it has potential as a research tool which is, as yet, largely unexplored. ...
AORTIC VALVE STENOSIS: FROM FORMULA TO GUIDELINE
... The precise diagnosis and knowledge of the disease hemodynamic impact are for that reason essential in clinical decision-making. ...
... The precise diagnosis and knowledge of the disease hemodynamic impact are for that reason essential in clinical decision-making. ...
7: Stable Ischemic Heart Disease - Welcome to the CardioSource
... proadrenomedullin (MRproADM), and midregionalproatrial natriuretic peptide (MRproANP) were most strongly related to CV outcomes, although incremental improvement over established risk factors was small, even after combining markers.22 Based on the evidence that biomarkers can offer improved ri ...
... proadrenomedullin (MRproADM), and midregionalproatrial natriuretic peptide (MRproANP) were most strongly related to CV outcomes, although incremental improvement over established risk factors was small, even after combining markers.22 Based on the evidence that biomarkers can offer improved ri ...
AHA Scientific Statement
... with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation. 2015;131:1123–1149. Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit http://my.amer ...
... with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation. 2015;131:1123–1149. Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit http://my.amer ...
Amlodipine in hypertension: a first
... What is already known about this subject? ▸ It is well known that many antihypertensive medications reduce the risk of stroke and heart attack. This is generally believed to be a class effect however. ...
... What is already known about this subject? ▸ It is well known that many antihypertensive medications reduce the risk of stroke and heart attack. This is generally believed to be a class effect however. ...
Preparatory Balloon Aortic Valvuloplasty During Transcatheter Aortic
... increased mortality associated with PAR after TAVI. Endpoint. The primary endpoint was mortality over the duration of the study according to Valve Academic Research Consortium II definitions (19). All patients were followed for at least 1 year. Post-interventional protocol. After TAVI, patients were ...
... increased mortality associated with PAR after TAVI. Endpoint. The primary endpoint was mortality over the duration of the study according to Valve Academic Research Consortium II definitions (19). All patients were followed for at least 1 year. Post-interventional protocol. After TAVI, patients were ...
Human coronary sinus — from Galen to modern times
... searched distribution of substances thus discovering systemic circulation. His methods were next improved by Svammerdam and Ragnier de Graaf. At that time anatomic specimens were composed by application of various filling media such as air, water or liquid pigments. During preparation injected vesse ...
... searched distribution of substances thus discovering systemic circulation. His methods were next improved by Svammerdam and Ragnier de Graaf. At that time anatomic specimens were composed by application of various filling media such as air, water or liquid pigments. During preparation injected vesse ...
PHYSIOLOGY OF ADVENTURE RACING
... The overall aims of this thesis were to elucidate the circulatory responses to ultra-endurance exercise (Adventure Racing), and furthermore, to contribute to the clarification of the so called “exercise-induced cardiac fatigue” in relation to said exercise. An Adventure race (AR) varies in duration ...
... The overall aims of this thesis were to elucidate the circulatory responses to ultra-endurance exercise (Adventure Racing), and furthermore, to contribute to the clarification of the so called “exercise-induced cardiac fatigue” in relation to said exercise. An Adventure race (AR) varies in duration ...
What You Should Know About Your Pacemaker Patient Manual
... that starts in a single area in the ventricle. The rate is usually faster than 120 beats per minute (bpm). ...
... that starts in a single area in the ventricle. The rate is usually faster than 120 beats per minute (bpm). ...
Left-to-Right Shunt Lesions
... performance in the patient with a left-to-right shunt include the Frank-Starling mechanism, the sympathetic nervous system, and hypertrophy of the myocardium. Sweating and tachycardia are manifestations of these compensatory mechanisms in infants with left-to-right shunt lesions. Infants are typical ...
... performance in the patient with a left-to-right shunt include the Frank-Starling mechanism, the sympathetic nervous system, and hypertrophy of the myocardium. Sweating and tachycardia are manifestations of these compensatory mechanisms in infants with left-to-right shunt lesions. Infants are typical ...
Inspection of Neck Veins - Turner White Communications
... venous pressure declines. However, in certain pathologic conditions the mean jugular venous pressure increases during inspiration: this clinical finding is known as Kussmaul’s sign.10 Kussmaul’s sign can be explained by the inability of the heart to accommodate increased venous return caused by nega ...
... venous pressure declines. However, in certain pathologic conditions the mean jugular venous pressure increases during inspiration: this clinical finding is known as Kussmaul’s sign.10 Kussmaul’s sign can be explained by the inability of the heart to accommodate increased venous return caused by nega ...
Alternative venous drainage of heart ventricles in rabbits
... ventricle and apex cordis. Often originated as two veins in the distal third of the heart (Fig. 4). Branches of the VMVS were observed to anastomose with the collateral branches of the VIP in 17% of cases (Fig. 1B) and with the MCV in 3% of cases. A double vein was seen in 3% of cases. The VMVS open ...
... ventricle and apex cordis. Often originated as two veins in the distal third of the heart (Fig. 4). Branches of the VMVS were observed to anastomose with the collateral branches of the VIP in 17% of cases (Fig. 1B) and with the MCV in 3% of cases. A double vein was seen in 3% of cases. The VMVS open ...
Fulltext: english,
... In trained and functionally fit athletes with a healthy heart, acute cardiovascular incidents due to training are very scarce. Regular physical exercise, controlled and adapted to physical conditions has beneficial effects surpassing hazards. If the principles of physical training are considered, po ...
... In trained and functionally fit athletes with a healthy heart, acute cardiovascular incidents due to training are very scarce. Regular physical exercise, controlled and adapted to physical conditions has beneficial effects surpassing hazards. If the principles of physical training are considered, po ...
Epicardial and visceral fat are independent determinants of diastolic
... 3.1. Diastolic function and adiposity parameters As shown in table A.2, there was a significant correlation between BMI and decreased early diastolic velocity (E’ lateral) and increased LV filling pressures (E/E’ mean). Fat mass percentage, assessed by bioelectric impedance analysis, was also inver ...
... 3.1. Diastolic function and adiposity parameters As shown in table A.2, there was a significant correlation between BMI and decreased early diastolic velocity (E’ lateral) and increased LV filling pressures (E/E’ mean). Fat mass percentage, assessed by bioelectric impedance analysis, was also inver ...
Catheter Ablation of the Pulmonary Veins as Treatment of Atrial
... symptomatic paroxysmal or persistent AF who have failed treatment with antiarrhythmic drugs (n=4 trials (9,11-13)); and (3) patients with symptomatic AF and heart failure who have failed treatment with standard medications for rate control and who would otherwise be considered for AV nodal ablation ...
... symptomatic paroxysmal or persistent AF who have failed treatment with antiarrhythmic drugs (n=4 trials (9,11-13)); and (3) patients with symptomatic AF and heart failure who have failed treatment with standard medications for rate control and who would otherwise be considered for AV nodal ablation ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.